Plozalizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Plozalizumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CCR2
Clinical data
Synonyms hu1D9
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Formula C6490H10052N1736O2018S42
Molar mass 146.0 kDa

Plozalizumab (hu1D9) (INN) is a humanized monoclonal antibody designed for the treatment of diabetic nephropathy and arteriovenous graft patency.[1][2]

This drug was developed by Takeda Pharmaceuticals International Co.

References[edit]